Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High- and low-dose radiotherapy plus tislelizumab in advanced ovarian cancer
ChiCTR2500111124Phase 2Not yet recruiting
- Sponsor
- Yichun People's Hospital
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in ovarian cancer, sponsored by Yichun People's Hospital. Primary endpoint: Objective Response Rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2500111124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111124.